FDA Expands Approval for Tocilizumab Biosimilar to Treat CRS

FDA Expands Avtozma to Include Cytokine Release Syndrome Treatment for Adults and Children

Originally approved earlier this year for multiple inflammatory conditions, including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis and COVID-19-related inflammation, Avtozma now aligns fully with the FDA-approved indications of its biosimilar, Actemra.

FDA Expands Approval for Tocilizumab Biosimilar to Treat CRS

FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients undergoing CAR T-cell therapy.

FDA expands AVTOZMA IV approval to include cytokine release syndrome

Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US